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Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy, affecting 4–12% of
reproductive-aged women. Women with PCOS often exhibit many metabolic abnormalities that are associated
with an increased cardiovascular disease (CVD) risk, independent of obesity. Exercise interventions from 12 to
24 weeks have been shown to have positive effects on blood lipid profile, ovulation and insulin resistance in
women with PCOS. However, no consensus on which exercise interventions are effective (i.e. duration, type of
exercise, frequency), including for different phenotypes, currently exists. The aim of this systematic review and
meta-analysis is to define effective types of exercise interventions to improve cardiometabolic profile, across
the range of phenotypes of PCOS.
Methods: We will conduct electronic database searches, including randomised-controlled trials (RCT), quasi-
RCT and clinical trials. Primary outcomes sought will be lipid profile, carotid-intima media thickness, fasting
blood glucose, %HbA1c, blood pressure, waist circumference, waist-to-hip ratio, abdominal adiposity and
inflammation markers. Secondary outcomes sought will be free and total testosterone, sex hormone binding
globulin and insulin resistance. The Cochrane Risk Assessment Tool will be used to assess study quality. Data
will be analysed in RevMan. Analysis of heterogeneity will be undertaken using the I2 statistic. Significant
heterogeneity will be explored, and sensitivity analyses carried out as appropriate. A subgroup analysis based
on androgen profile will be undertaken if data are sufficient.
Discussion: A large proportion of women are affected by PCOS. It is prudent to examine how CVD risk can be
mitigated in this high-risk population, and this review aims to provide evidence-driven recommendations on the types
of exercise interventions that are effective for this. The review will seek to provide recommendations regarding type,
frequency and duration of exercise interventions to improve cardiometabolic profile in PCOS. The subgroup analysis
may be able to highlight difference in intervention effects between normo-androgenic and hyper-androgenic profile.
Limitations include heterogeneity across studies and a scarcity of clinical trials involving a PCOS control group not
undertaking any intervention.
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Background
Introduction to polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy, with 4–12% of reproductive-aged
women affected [1]. The typically used diagnostic criteria
in the UK are the Rotterdam Criteria, which resulted
from a conference sponsored by the European Society of
Human Reproduction and Embryology (ESHRE) and the
American Society for Reproductive Medicine (ASRM)
[2]. The Rotterdam Criteria requires that women present
with at least two of the three signs/symptoms to receive
a diagnosis [2]. Those three criteria are clinical or bio-
chemical hyperandrogenism, anovulation or oligomenor-
rhea, and polycystic ovaries, in the absence of other
pathologies that can promote these symptoms [2].
Women with PCOS often exhibit many metabolic ab-
normalities that are associated with an increased CVD
risk, independent of obesity [3]. These include insulin
resistance, impaired glucose tolerance (IGT), dyslipidae-
mia, type 2 diabetes (T2D), hypertension, subclinical
atherosclerosis, abdominal obesity, and a two to fourfold
higher prevalence of metabolic syndrome compared to
body mass index (BMI)-matched women [4–7]. It has
been reported that the prevalence of T2D among women
with PCOS is 2.6 times higher than that of the general
female population [8]. This risk steadily increases with
BMI and is particularly high for obese women [8].
However, it is not clear, due to a lack of long-term
follow-up studies, whether this increased risk is solely
attributed to obesity. It is estimated that 33% to 50%
of women with PCOS are overweight or obese [9],
which indicates that obesity is not the only factor in-
fluencing the prevalence or severity of PCOS [9]. Dys-
lipidaemia, characterised by high triglyceride (TG)
and low high-density lipoprotein (HDL) concentra-
tions, is prevalent in up to 70% of women with PCOS
[5]. Consequently, women with PCOS have a 50% in-
creased risk of cardiovascular events compared to
their weight-matched counterparts [6].
Inflammatory markers that are implicated in the medi-
ation of CVD have been reported to be increased in
PCOS [10]. These range from high-sensitivity C-reactive
protein [11, 12] to increased white cell count, neutro-
phil/lymphocyte ratio, tumour-necrosis factor-alpha
(TNF-a), and interleukin-6 (IL-6) [12–15]. Moreover,
various studies have reported that carotid intima-media
thickness (cIMT), a marker of subclinical atherosclerosis,
is higher in PCOS women compared to controls [16].
Lifestyle interventions and modifications are widely
considered to be a cornerstone of PCOS treatment for
cardiometabolic symptoms [2, 17]. A 2011 systematic re-
view examining the effects of exercise interventions on
PCOS found improvements in lipid profile, ovulation,
and insulin sensitivity by up to 30%, independent of
weight loss, within 12 weeks and across eight studies
[18]. This is important for lean women with PCOS who
present with insulin resistance and associated CVD risk
factors, because they may still benefit from exercise des-
pite their normal BMI. However, it does appear that
positive results are maximised when exercise is concur-
rent with weight loss, and this appears to be achievable
through longer duration interventions [18].
Various systematic reviews have been conducted to
identify the effects of lifestyle interventions in PCOS, to
the authors’ knowledge, there have been no recent re-
views that isolate the effects of exercise and exclude
studies with lifestyle interventions, with a meta-analysis
conducted on cardiometabolic outcomes.
Therefore, the current systematic review and
meta-analysis aim to provide data-backed recommen-
dations on type, frequency, and duration of exercise
interventions specifically aiming to improve cardio-
metabolic profile in women with PCOS via the fol-
lowing objectives:
1. Conduct an updated systematic review that will
include primary studies published up to April 2018.
2. Undertake an in-depth analysis of cardiometabolic
outcomes solely, without sharing the focus with
fertility-related outcomes.
3. Dependent on sufficient androgen data, aim to
partition results based on androgen profile, such
that any difference between normo-androgenic and
hyper-androgenic phenotypes will be highlighted.
4. Include only control groups containing women with
PCOS undertaking no intervention or standard
care, so that the effects of exercise can be isolated.
Methods
The review will be reported in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidance. This protocol has
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been summarised according to the Preferred Report-
ing Items for Systematic review and Meta-Analysis
Protocols (PRISMA-P) and has been registered in the
International Prospective Register of Systematic Re-
views (PROSPERO).
Eligibility criteria
RCT, quasi-RCT and clinical trials will be screened ac-
cording to population, intervention, comparison, and
outcome (PICO) criteria as highlighted in Table 1:
Searches
The electronic databases as follows will be searched
from inception to present: CINAHL Complete (EBSCO),
Cochrane Central Register of Controlled Trials (CEN-
TRAL) (Wiley), MEDLINE (EBSCO), Scopus (Elsevier),
SPORTDiscus (EBSCO), PEDro (The University of Syd-
ney) and PubMed (US National Library of Medicine).
Clinical trials will be sought via searches of Clinical-
Trials.gov and UK Clinical Trials Gateway. Only English
language publications will be sought, and no publication
date limitations will be applied.
The search terms will be PCOS or polycystic ovary
syndrome and terms relating to exercise or physical ac-
tivity interventions. These will be adapted for use in
other databases.
The PubMed search strategy can be found in the
Appendix.
Data collection and analysis
Study selection
Results from the database searches will be imported into
RefWorks and de-duplicated once the searches are
complete. The title and abstract for each paper will then
be exported to Microsoft Excel. Screening will be under-
taken in Microsoft Excel, with one reviewer (AW)
screening each result. A second reviewer (MK and DB)
will screen each result in duplicate. Cohen’s kappa statis-
tic will be used to determine inter-rater reliability.
The full-text will then be retrieved for each of the ini-
tially included studies, such that they can be examined
in more detail to determine their relevancy. This will be
undertaken by AW with screening undertaken in dupli-
cate by a second reviewer (MK or DB). A reason will be
provided for any studies excluded at this stage. Through-
out this stage, disagreement between two reviewers will
result in discussion and input from a third reviewer until
a consensus is reached. Where the full-text is not avail-
able, a request will be made to the British Library.
Data extraction
A data extraction form will be created in Microsoft Excel
which will be piloted using at least two studies. One re-
viewer will extract data using the form, and all data will
be double-checked for consistency by a second reviewer
(MK or DB).
Extracted data will include bibliographic information
(such as title, journal, primary author, publication date,
Table 1 Inclusion and exclusion criteria
PICO Inclusion criteria Exclusion criteria
Population Diagnosed with PCOS according to the Rotterdam Criteria 2003,
National Institute of Health (NIH) 1990 criteria or Androgen Excess
and Polycystic Ovary Syndrome (AE-PCOS) Society 2006 criteria.
Be post-menarche and pre-menopausal.
Be inactive (< 150min/week of moderate-to-high intensity physical
activity).
Receiving fertility treatment, taking metformin or OCP, or
having a diagnosis of any pathology that may be promoting
PCOS symptoms such as Cushing’s syndrome, congenital
hyperplasia or androgen-secreting tumour.
Intervention Any sample size.
Aerobic exercise training, anaerobic exercise training, resistance training
or combinations.
At least 2 weeks of structured, supervised sessions.
Interventions including multiple arms (such as aerobic and anaerobic
exercise training, or a medication arm) will be included if it is possible
to isolate the effects of the exercise intervention through a control
group or placebo.
Crossover trials and interventions that are combined (such
as lifestyle intervention including both exercise and diet
management—where diet management refers to participants
actively changing their caloric intake or the macronutrient
composition of their diet in response to given targets).
Comparison A control group of women with PCOS undertaking no interventions.
No intervention is defined as not taking part in any structured exercise
training and not receiving fertility treatment, metformin, oral
contraceptive pill (OCP) or statins.
Healthy control group.
Outcome Primary outcomes will be low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC),
TC:HDL ratio, TG, oxidised LDL, cIMT, fasting glucose, HbA1c, blood
pressure, waist circumference (WC), waist-to-hip ratio (WHR), abdominal
adiposity and inflammation markers.
Secondary outcomes will be total testosterone, free testosterone, sex
hormone binding globulin (SHBG), fasting insulin and homeostatic
model assessment for insulin resistance (HOMA-IR).
Outcome measures that have not been recorded at baseline
and post intervention.
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count and type of study arms and sample sizes), study
characteristics (such as study design, count and type of
study arms and sample sizes), participant characteristics
(such as age and BMI and PCOS diagnostic criteria),
intervention and comparison data (such as type of con-
trol group, type, duration and frequency of exercise
intervention, randomisation and withdrawal) and out-
come data including any relevant parameters named in
the primary and secondary outcomes, taken at baseline
before intervention, and post-intervention, for each arm.
In the case of any missing or unclear data, two at-
tempts will be made to contact the corresponding au-
thor by email. If no response is received, the study will
be excluded. Data will be extracted as mean and stand-
ard deviation (SD) for baseline and post-intervention
values. P values and confidence intervals will also be ex-
tracted if available.
Risk of bias in individual studies and heterogeneity
The Cochrane Risk Assessment Tool will be used to as-
sess quality at the study level. The tool evaluates studies
based on six criteria: (1) randomisation generation, (2)
allocation concealment, (3) blinding of outcome asses-
sors, (4) incomplete outcome data (that is, lost to
follow-up), (5) selective outcome reporting and (6) other
risks of bias. Because it is not possible to blind partici-
pants to their intervention allocation due to the de-
mands of studies requiring engagement with exercise
programmes, we did not include this domain in the risk
assessment.
Heterogeneity of results will be assessed using the I2
statistic. This statistic measures the consistency of re-
sults across studies, that is, whether the variation in out-
comes across studies is due to chance (homogeneity) or
whether there are genuine, underlying differences be-
tween the studies (heterogeneity) [19]. This statistic has
been chosen for its simplicity and applicability to
meta-analyses regardless of the number of studies in-
volved [19]. A result of over 50% will be considered sig-
nificant heterogeneity. We will then choose whether a
random effect or fixed effect model will be most appro-
priate for meta-analysis. Sensitivity analyses will be per-
formed as appropriate.
Data synthesis
Data that meets the inclusion criteria of outcomes mea-
sured and presented pre- and post-intervention will be
quantitatively synthesised. Outcomes will be recorded in
tables outlining means and standard deviation, with ef-
fect size expressed as mean difference (difference be-
tween means) with 95% confidence intervals and study
weighting. The mean difference will be calculated as the
difference between final (post-intervention) values rather
than change scores. This is because baseline and final
values may be reported for different numbers of partici-
pants due to missed visits or study withdrawals, leading
to inaccurate change scores [20]. In addition, change
scores are often not presented with standard deviations
and imputing them may be inappropriate because of dif-
ferences between studies [20]. However, in cases where
there are significant differences at baseline, change
scores may be used if it is appropriate to impute SD. In
cases where only the change score is available, efforts
will be made to contact authors to obtain final value
scores. If this is not possible, change scores will be in-
cluded if presented with a SD. If there is no SD, it may
be imputed where appropriate.
Data will be parsed according to the review question,
i.e. by type, duration and frequency of intervention. For-
est plots will be generated and a P value of < 0.05 will be
considered statistically significant.
Statistical analysis will be undertaken using RevMan
5 [21].
Subgroup analysis
If enough androgen data is available, data will be parti-
tioned into normo-androgenic or hyper-androgenic pro-
files, based on a free testosterone measure, where > 11
pmol/L indicates hyper-androgenism [22]. Hence, differ-
ences between these phenotypes will be highlighted.
To perform the subgroup analysis, free testosterone
data is needed and a sufficient level of homogeneity
between such studies to parse the results by androgen
profile. If this is inappropriate, descriptive statistics
and commentary will be provided in place of a formal
meta-analysis.
If data are available, subgroup analysis will be per-
formed on type, frequency and duration of exercise
intervention.
Confidence in findings
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) will be used to grade
the quality of the evidence and the strength of a finding.
GRADE provides a systematic and explicit approach to
making judgements about clinical and healthcare guide-
lines and recommendations, based on the quality of the
evidence behind them. The use of a consistent and
transparent approach to evaluating recommendations in-
creases the facilitation of critical appraisal and improves
communication of these judgements [23].
Discussion
PCOS is a complex hormonal and metabolic disorder
characterised by higher amounts of visceral fat, obesity,
dyslipidaemia and insulin resistance. It is associated with
reproductive and cardiometabolic complications. Man-
agement of PCOS is usually dependent on both the
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symptoms and suspected causes of PCOS. However,
since PCOS is often presumed to be the result of an
endocrine system feedback loop, it can be a challenge to
isolate a single influence [24]. Thus, treatment modes
vary, encompassing drug treatment with metformin or
the oral contraceptive pill (OCP) [25], surgery [26] and
alternative treatments such as acupuncture [27].
Phenotypes that present with hyperandrogenism have
been shown to have a worse metabolic profile and in-
creased risk factors than other phenotypes, despite com-
parable distributions of body weight [28, 29]. This may be
because insulin acts as a co-gonadotrophin to stimulate
ovarian androgen production, and thus hyperinsulinaemia
and the severity of insulin resistance is associated with in-
creased circulating androgen concentrations [24]. Indeed,
the increased circulating androgens may then contribute
to the accumulation of abdominal fat, further exacerbating
insulin resistance. Increased androgens may also play a
role in inflammation in PCOS, by promoting adipocyte
hypertrophy and increasing mononuclear cell sensitivity
to glucose, which in turn stimulates mononuclear cells to
release TNF-a and IL-6 [30].
Although exercise interventions have been conducted
with women with PCOS, there are no guidelines for the
higher risk phenotype, or indeed any guidance on which
exercise interventions are most effective for differing
phenotypes, regarding duration, type of exercise, and fre-
quency of exercise sessions. Furthermore, no reviews
have attempted to highlight the difference between the
normo-androgenic and hyper-androgenic phenotypes of
PCOS in response to exercise interventions. Subse-
quently, the objective of this systematic review and
meta-analysis is to define effective types of exercise in-
terventions to improve cardiometabolic profile, across
the range of phenotypes of PCOS.
Potential limitations include heterogeneity across stud-
ies due to the inclusion of exercise interventions of all
types/durations/frequencies and a scarcity of clinical tri-
als involving a control group that not only has PCOS,
but also is not undertaking any other intervention; many
of the exercise trials for PCOS involve a diet or ‘lifestyle’
intervention arm, whereas this review will look to isolate
the effects of exercise. A further limitation is that only
studies published in the English language will be in-
cluded; this has the potential to introduce language or
cultural bias.
Appendix
The search was performed using PubMed syntax as
demonstrated below, and amended for other databases:





6. (1 OR 2 OR 3 OR 4 OR 5)
7. Exercise[majr]
8. exercise therapy [majr]
9. Physical activity [majr]
10. Physical Fitness [majr]
11. Physical Endurance[majr]
12. exercis*[tw]
13. ((physical or motion) AND (fitness or therapy or
therapies))[tw]
14. ((strength or resistance or circuit or enduran* or
aerob* or physic* or fit*) AND train*)[tw]
15. (7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14)
16. (6 AND 15)
((((((("polycystic ovary syndrome"[Title/Abstract]) OR
PCOS[Title/Abstract]) OR PCO*[Title/Abstract]) OR
polycystic ovar*[Title/Abstract]) OR stein leventhal[Ti-
tle/Abstract]))) AND (((((((Exercise[majr]) OR exercise
therapy [majr]) OR Physical activity [majr]) OR Physical
Endurance[majr]) OR exercis*[tw]) OR (((physical or
motion) AND (fitness or therapy or therapies))[tw])) OR
(((strength or resistance or circuit or enduran* or aerob*
or physic* or fit*) AND train*)[tw]))
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